Optimizing PrEP Uptake & Adherence Among Male Sex Workers (MSW) Using a 2-stage Randomization Design
Optimizing Pre-exposure Prophylaxis (PrEP) Uptake & Adherence Among MSW Using a 2-stage Randomization Design
1 other identifier
interventional
111
1 country
2
Brief Summary
"PrEPare for Work" is a two-stage randomized controlled pilot trial which utilizes a behavioral intervention to optimize the uptake and adherence of Pre-exposure Prophylaxis (PrEP) in Male Sex Workers (MSW).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2017
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2017
CompletedFirst Posted
Study publicly available on registry
March 22, 2017
CompletedStudy Start
First participant enrolled
May 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2019
CompletedResults Posted
Study results publicly available
March 15, 2021
CompletedMarch 15, 2021
February 1, 2021
2.6 years
March 8, 2017
February 3, 2021
February 22, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Number of Participants With Verified Attendance at Initial Appointment at PrEP Clinic
Number of participants with attendance at initial appointment at PrEP Clinic verified using medical records
2-month post Stage 1 randomization
Number of Participants Who Initiated PrEP
Initial prescription from provider filled and shown to study staff
2-month post Stage 1 randomization
Number of Participants Reporting Optimal PrEP Adherence
Self-reporting missing 0 PrEP pills in the past week
6-months post Stage 2 randomization
Study Arms (4)
Strength Based Case Management
EXPERIMENTALStage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
PrEP adherence training and counseling
EXPERIMENTALStage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
Standard of Care:Stage 1
NO INTERVENTIONStage 1: Referral to The Miriam Hospital PrEP Clinic.
Standard of Care: Stage 2
NO INTERVENTIONStage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
Interventions
Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
Eligibility Criteria
You may qualify if:
- years of age or older
- Biological male at birth and current male gender identity
- Exchanged sex for money or drugs with another man in the past 3 months
- Report behavioral risk for HIV infection, consistent with Centers for Disease Control and Prevention guidelines for prescribing PrEP: condomless anal intercourse with at least one HIV-infected or unknown serostatus partner in the past three months
- HIV uninfected by antibody test\* Stage 2
- Able to understand and speak English (for consent and counseling)
- Mental competency to provide voluntary informed consent
- Lives in the New England area
- Willing to initiate PrEP
You may not qualify if:
- Unable to provide informed consent, including as a result of severe mental illness requiring immediate treatment or mental illness limiting the ability to participate
- HIV Positive at baseline
- Infected with Hepatitis B or diagnosed with renal insufficiency (glomerular filtration rate \< 50) \*Stage 2
- History of or current medical conditions that would preclude taking Truvada for PrEP \*Stage 2
- Currently taking Truvada for PrEP
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brown Universitylead
- The Miriam Hospitalcollaborator
Study Sites (2)
The Miriam Hospital
Providence, Rhode Island, 02906, United States
Brown University School of Public Health
Providence, Rhode Island, 02912, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Due to COVID, we are delayed in receiving the results of our biomarkers (specifically, hair analysis for PrEP adherence).
Results Point of Contact
- Title
- Dr. Katie Biello
- Organization
- Brown University
Study Officials
- PRINCIPAL INVESTIGATOR
Matthew J Mimiaga, ScD, MPH
Brown University, School of Public Health, Center for Health Equity Research
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- ScD, MPH
Study Record Dates
First Submitted
March 8, 2017
First Posted
March 22, 2017
Study Start
May 1, 2017
Primary Completion
December 15, 2019
Study Completion
December 15, 2019
Last Updated
March 15, 2021
Results First Posted
March 15, 2021
Record last verified: 2021-02
Data Sharing
- IPD Sharing
- Will share
It is anticipated that this data will be presented annually on data collected after the second year when sufficient baseline data is collected. It is anticipated that most of the papers and data-based projects/presentations will happen in year 3, when all of the baseline data is collected, and the 3 month outcome has occurred for all participants. Sharing of the findings will involve a primary paper describing the study outcome and a paper that describes the intervention, as well as submitting to lead workshops on the intervention approach at relevant national meetings and conferences. Raw data for additional analysis will be available to outside individuals through contacting the MPIs. Information regarding the availability of data for analysis will be listed on the MPIs' web pages. Contact information for the MPIs will be listed in all manuscripts and publications as another means to access data.